X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Titan Pharmaceuticals has granted an exclusive license to Ocular Therapeutix pertaining to certain patent applications for ophthalmic uses in both humans and nonhuman animals.
Lead Product(s): Undisclosed
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Ocular Therapeutix
Deal Size: $0.1 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 12, 2022
Details:
The implant utilises Titan's proprietary ProNeura™ drug delivery system and combines nalmefene with an ethylene-vinyl acetate (EVA) polymer,l for long-term treatment options in addiction medicine.
Lead Product(s): Nalmefene Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2022
Details:
The funding will support the demonstration of its ability to deliver a human immunodeficiency virus ("HIV") preventative therapeutic and a contraceptive from a single implant using its proprietary ProNeura® technology.
Lead Product(s): Antiviral drug,Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding October 25, 2021
Details:
Under the terms of the Agreement, Titan will conduct research, evaluation, proof of concept development and testing of at least three tetrapeptide kappa-opioid receptor agonist compounds including TP-2021 (formerly JT-09), for use in combination with the ProNeura technology.
Lead Product(s): TP-2021
Therapeutic Area: Dermatology Product Name: TP-2021
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: MUSC Foundation for Research Development
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 12, 2021
Details:
JT-09 is being developed for use in combination with Titan's ProNeura® long-term, continuous drug delivery technology for the treatment of moderate-to-severe chronic pruritus (itch).
Lead Product(s): JT-09
Therapeutic Area: Dermatology Product Name: JT-09
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2021
Details:
As a result of the debt settlement with Molteni and Horizon, there are no liens remaining on any of Titan's assets. With the net proceeds from recent public the company is well positioned to progress preclinical development of its ProNeura-based pipeline and JT-09.
Lead Product(s): JT-09
Therapeutic Area: Dermatology Product Name: JT-09
Highest Development Status: PreclinicalProduct Type: Peptide
Recipient: Molteni Farmaceutici
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering November 02, 2020
Details:
Titan has acquired JT Pharma's kappa opioid agonist peptide, JT-09, for use in combination with Titan's ProNeura® long-term, continuous drug delivery technology, for the treatment of chronic pruritus.
Lead Product(s): JT-09
Therapeutic Area: Dermatology Product Name: JT-09
Highest Development Status: UndisclosedProduct Type: Peptide
Recipient: JT Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 28, 2020
Details:
The partnership will establish multichannel digital marketing programs throughout the United States and expand the capabilities for the engagement of health care providers ("HCPs") who are eligible to prescribe Titan's Probuphine® (buprenorphine) implant.
Lead Product(s): Buprenorphine
Therapeutic Area: Psychiatry/Psychology Product Name: Probuphine
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Indegene Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
